Google AI
NewsPronto

 

ACN Newswire

Read more press releases from ACN Newswire here

Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.

  • Written by: ACN Newswire

image

- Multi-arm trial targets sub-population of advanced lung, and head and neck cancer patients- Medium term objective is to transform non-responders into checkpoint inhibitor responders while improving patient benefits- Trial aims to evaluate the ability of NBTXR3 to generate an abscopal effect- Expands the potential for NBTXR3, including recurrent...

Read more: Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune...